PB1-3
PB1-3 is an orally active CDK4/CDK6 inhibitor with selective antiproliferative activity against 4T1 and MCF-7 breast cancer cells. PB1-3 directly binds to CDK4 and CDK6, downregulates total protein expression, reduces Rb phosphorylation, and induces G0/G1 phase arrest. PB1-3 induces ROS accumulation, mitochondrial membrane potential collapse, initiation of mitochondria-mediated intrinsic apoptosis, upregulation of the Bax/Bcl-2 ratio, and activation of cleaved caspase-3. PB1-3 inhibits tumor growth in a 4T1 orthotopic syngeneic mouse model. PB1-3 can be used for research related to triple-negative breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 113062-58-1
- Formula: C20H24O4
- Molecular Weight:328.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK4 |
CDK6 |
Bax |
Bcl-2 |
Caspase 3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
3.13 μM
|
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
| 4T1 | IC50 |
4.28 μM
|
Antiproliferative activity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
| HepG2 | IC50 |
8.48 μM
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
| HeLa | IC50 |
9.18 μM
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
| HUVEC | IC50 |
69.96 μM
|
Antiproliferative activity against human HUVECs assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against human HUVECs assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
| HK-2 | IC50 |
66.35 μM
|
Antiproliferative activity against human HK-2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against human HK-2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
| NIH3T3 | IC50 |
187.86 μM
|
Antiproliferative activity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
| H9c2 | IC50 |
185.71 μM
|
Antiproliferative activity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
Antiproliferative activity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay.
|
42571741 |
In Vitro
PB1-3 (0-20 μM; 24 h) exhibits potent antiproliferative activity against MCF-7 and 4T1 breast cancer cell lines with high selectivity over normal cells, with IC50 values of 3.13 μM and 4.28 μM, respectively[1].
PB1-3 (2.5-10 μM; 0-24 h) effectively inhibits the migration of MCF-7 and 4T1 cells in a concentration-dependent manner[1].
PB1-3 (1.25-20 μM; 48 h treatment, followed by 10-14 days of culture) effectively inhibits the clonogenic survival of MCF-7 and 4T1 cells in a dose-dependent manner[1].
PB1-3 stably binds CDK4 and CDK6 with high affinity and favorable binding free energy, forming stable complexes through hydrogen bonds and hydrophobic interactions[1].
PB1-3 (2.5-10 μM; 24 h) modulates the CDK4/6-Rb pathway by downregulating total CDK4 and CDK6 protein levels and reducing Rb phosphorylation in MCF-7 and 4T1 cells[1].
PB1-3 (2.5-10 μM; 24 h) induces strong and concentration-dependent intracellular reactive oxygen species accumulation in MCF-7 and 4T1 cells; it induces mitochondrial dysfunction by collapsing the mitochondrial membrane potential in a concentration-dependent manner[1].
PB1-3 (2.5-10 μM; 24 h) induces apoptosis and G0/G1 cell cycle arrest in MCF-7 and 4T1 cells in a concentration-dependent manner; it activates the intrinsic apoptotic pathway in MCF-7 and 4T1 cells by increasing the Bax/Bcl-2 ratio and activating caspase-3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7, 4T1, HepG2, HeLa, HUVECs, HK-2, NIH3T3, and H9c2
-
Concentration:0, 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 μM
-
Incubation Time:24 h
-
Result:Exhibited the most potent antiproliferative activity toward MCF‑7 (IC50 = 3.13 μM) and 4T1 (IC50 = 4.28 μM) cells. Showed antiproliferative effects against HepG2 (IC50 = 8.48 μM) and HeLa (IC50 = 9.18 μM) tumour cells. Displayed much higher IC50 values in normal cell lines: HUVECs at 69.96 μM, HK‑2 at 66.35 μM, NIH3T3 at 187.86 μM, and H9c2 at 185.71 μM.
-
Cell Line:MCF-7 and 4T1 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:0, 12, 24 h
-
Result:Resulted in a significant, concentration-dependent inhibition of cell migration.
At a concentration of 10 μM, almost completely inhibited wound closure in both 4T1 and MCF-7 cells after 24 h.
-
Cell Line:4T1 and MCF-7 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Induced a significant and concentration-dependent increase in the percentage of apoptotic cells.
At 10 μM, the total apoptosis rate reached 49.94% in 4T1 cells and 53.89% in MCF-7 cells.
-
Cell Line:4T1 and MCF-7 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Resulted in a significant and concentration-dependent accumulation of cells in the G0/G1 phase, with a concomitant decrease in the percentage of cells in the S and G2/M phases.
-
Cell Line:4T1 and MCF-7 cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Led to a marked upregulation of Bax and a simultaneous downregulation of Bcl-2, resulting in a significant increase in the Bax/Bcl-2 ratio.
Consequently, the activation of cleaved caspase-3 was significantly increased in a dose-dependent manner.\nSignificantly downregulated the protein expression levels of CDK4 and CDK6 in both 4T1 and MCF-7 cells.
The phosphorylation of the retinoblastoma protein (p-Rb) was dramatically reduced.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | T1/2 | AUC0-t | AUC0-∞ |
|---|---|---|---|---|---|---|---|
| Mice[1] | 20 mg/kg | p.o. | 259.3 ng/mL | 1 h | 3.0 h | 887.0 ng/mL·h | 889.5 ng/mL·h |
In Vivo
PB1-3 (500-2000 mg/kg; p.o.; single administration) exhibits an oral LD50 greater than 2000 mg/kg, shows no significant acute toxicity, and demonstrates a favorable safety profile[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice (6-8 weeks old, 20 g) were orthotopically injected with 4T1 cells (6 × 106 cells/mL, 100-150 μL into mammary fat pad near the third pair of mammary glands per mouse)[1]
-
Dosage:10 mg/kg; 15 mg/kg; 20 mg/kg
-
Administration:i.p.; every two days; total of 6 doses
-
Result:Suppressed tumor growth in a dose-dependent manner.
Achieved a marked reduction in both tumor volume and tumor weight at 20 mg/kg.
Showed antitumor activity comparable to that of Cisplatin (HY-17394) at 15 mg/kg.
Induced no significant body weight loss in any treated group.
Resulted in no significant differences in serum ALT, AST, BUN, and CRE levels compared to the vehicle control group.
Showed no obvious pathological abnormalities, necrosis, or inflammatory infiltration in major organs.
Chemical Information
-
CAS No. 113062-58-1
-
Molecular Weight 328.40
-
Formula C20H24O4
-
SMILES
COC1=CC=C2C(OC/C=C(CC/C=C(C)/C)\C)=CC(OC2=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)